Invesaro

Stocks Comparison

National Vision vs RxSight: revenue, profit, margins and growth compared

National Vision brought in $2B of revenue in fiscal 2025, RxSight $134.5M in fiscal 2025. Revenue changed by +9.0% at National Vision and -3.9% at RxSight on the year before, so National Vision grew faster. National Vision kept 1.5% of its revenue as net profit, RxSight -29.0%. Free cash flow was $73.5M at National Vision and -$19.3M at RxSight.

Side by side, latest fiscal year

EYERXST
Fiscal year endedFY2025 (January 3, 2026)FY2025 (December 31, 2025)
Revenue$2B$134.5M
Revenue growth+9.0%-3.9%
Net income$29.6M-$38.9M
Net margin1.5%-29.0%
Free cash flow$73.5M-$19.3M
Free cash flow margin3.7%-14.4%
Earnings per share (diluted)$0.37-$0.95
Cash$38.7M$19.9M
Debt$236.5Mn/a
Price to earnings44.7n/a
Market value$1.3B$193.8M
Dividend yieldn/an/a
Rank by revenue in sector#110 of 523 · Health care#279 of 523 · Health care

Over the years

Revenue
EYE FY2018: $1.5BEYE FY2019: $1.7BEYE FY2020: $1.7BEYE FY2021: $2.1BEYE FY2022: $1.6BEYE FY2023: $1.8BEYE FY2024: $1.8BEYE FY2025: $2BRXST FY2021: $14.7MRXST FY2021: $22.6MRXST FY2022: $49MRXST FY2023: $89.1MRXST FY2024: $139.9MRXST FY2025: $134.5MFY18FY19FY20FY21FY22FY23FY24FY25
EYE $2BRXST $134.5M
Net income
EYE FY2018: $23.7MEYE FY2019: $32.8MEYE FY2020: $36.3MEYE FY2021: $128.2MEYE FY2022: $42.1MEYE FY2023: -$65.9MEYE FY2024: -$28.5MEYE FY2025: $29.6MRXST FY2021: $27.6MRXST FY2021: -$48.7MRXST FY2022: -$66.8MRXST FY2023: -$48.6MRXST FY2024: -$27.5MRXST FY2025: -$38.9MFY18FY19FY20FY21FY22FY23FY24FY25
EYE $29.6MRXST -$38.9M
Net margin
EYE FY2018: 1.5%EYE FY2019: 1.9%EYE FY2020: 2.1%EYE FY2021: 6.2%EYE FY2022: 2.6%EYE FY2023: -3.8%EYE FY2024: -1.6%EYE FY2025: 1.5%RXST FY2021: 187.9%RXST FY2021: -215.5%RXST FY2022: -136.2%RXST FY2023: -54.6%RXST FY2024: -19.6%RXST FY2025: -29.0%FY18FY19FY20FY21FY22FY23FY24FY25
EYE 1.5%RXST -29.0%
Revenue growth
EYE FY2019: +12.2%EYE FY2020: -0.7%EYE FY2021: +21.5%EYE FY2022: -20.9%EYE FY2023: +6.8%EYE FY2024: +3.8%EYE FY2025: +9.0%RXST FY2021: +53.9%RXST FY2022: +116.9%RXST FY2023: +81.8%RXST FY2024: +57.1%RXST FY2025: -3.9%FY19FY20FY21FY22FY23FY24FY25
EYE +9.0%RXST -3.9%
Free cash flow
EYE FY2018: $2.1MEYE FY2019: $63.8MEYE FY2020: $158.2MEYE FY2021: $163.4MEYE FY2022: $5.7MEYE FY2023: $58.3MEYE FY2024: $38.1MEYE FY2025: $73.5MRXST FY2021: -$37.7MRXST FY2021: -$46.6MRXST FY2022: -$61.2MRXST FY2023: -$46.4MRXST FY2024: -$22.4MRXST FY2025: -$19.3MFY18FY19FY20FY21FY22FY23FY24FY25
EYE $73.5MRXST -$19.3M

Fiscal years as each company reports them; the two may end in different months.

Questions about National Vision and RxSight

Which is bigger by revenue, National Vision or RxSight?

National Vision is bigger by revenue: $2B in fiscal 2025, against $134.5M for RxSight in fiscal 2025.

Which keeps more of its revenue as profit, National Vision or RxSight?

National Vision had a net margin of 1.5% in fiscal 2025; RxSight had -29.0% in fiscal 2025.

Which grew revenue faster, National Vision or RxSight?

In their latest fiscal years revenue changed by +9.0% at National Vision and -3.9% at RxSight.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies